Search

Your search keyword '"Ilariucci F"' showing total 140 results
Start Over Author "Ilariucci F"
140 results on '"Ilariucci F"'

1. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Author

Morabito, Francesco, Tripepi, G., Mauro, F. R., Laurenti, Luca, Reda, G., Moia, R., Condoluci, A., Vincelli, I., Chiarenza, A., Vigna, E., Martino, E. A., Bruzzese, Maria Antonella, Mezzatesta, S., Laureana, R., Cutrona, G., Di Raimondo, F., Fronza, G., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Olivieri, J., Zaja, F., Rossi, Dario, Gaidano, G., Del Principe, M. I., Ilariucci, F., Del Poeta, G., Ferrarini, M., Neri, A., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Bruzzese A., Rossi F. M., Rossi D., Morabito, Francesco, Tripepi, G., Mauro, F. R., Laurenti, Luca, Reda, G., Moia, R., Condoluci, A., Vincelli, I., Chiarenza, A., Vigna, E., Martino, E. A., Bruzzese, Maria Antonella, Mezzatesta, S., Laureana, R., Cutrona, G., Di Raimondo, F., Fronza, G., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Olivieri, J., Zaja, F., Rossi, Dario, Gaidano, G., Del Principe, M. I., Ilariucci, F., Del Poeta, G., Ferrarini, M., Neri, A., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Bruzzese A., Rossi F. M., and Rossi D.

Abstract

NA

Published
2023

2. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY

Author

Chiappella, A., primary, Carniti, C., additional, Re, A., additional, Castellino, C., additional, Evangelista, A., additional, Ciancia, R., additional, Orsucci, L., additional, Pinto, A., additional, Usai, S. V., additional, Arcari, A., additional, Ilariucci, F., additional, Rossi, F. G., additional, Benedetti, F., additional, Flenghi, L., additional, Ghiggi, C., additional, Molinari, A. L., additional, Stefoni, V., additional, Volpetti, S., additional, Zilioli, V. R., additional, Ballerini, F., additional, Bruna, R., additional, Cavallo, F., additional, Musuraca, G., additional, Patti, C., additional, Re, F., additional, Tani, M., additional, Varettoni, M., additional, Zanni, M., additional, Dodero, A., additional, Pileri, S. A., additional, Ciccone, G., additional, and Corradini, P., additional

Published
2021
Full Text
View/download PDF

3. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

Author

Cuneo, A, Mato, AR, Rigolin, GM, Piciocchi, A, Gentile, M, Laurenti, L, Allan, JN, Pagel, JM, Brander, DM, Hill, BT, Winter, A, Lamanna, N, Tam, CS, Jacobs, R, Lansigan, F, Barr, PM, Shadman, M, Skarbnik, AP, Pu, JJ, Sehgal, AR, Schuster, SJ, Shah, NN, Ujjani, CS, Roeker, L, Orlandi, EM, Billio, A, Trentin, L, Spacek, M, Marchetti, M, Tedeschi, A, Ilariucci, F, Gaidano, G, Doubek, M, Farina, L, Molica, S, Di Raimondo, F, Coscia, M, Mauro, FR, de la Serna, J, Medina Perez, A, Ferrarini, I, Cimino, G, Cavallari, M, Cucci, R, Vignetti, M, Foa, R, Ghia, P, Cuneo, A, Mato, AR, Rigolin, GM, Piciocchi, A, Gentile, M, Laurenti, L, Allan, JN, Pagel, JM, Brander, DM, Hill, BT, Winter, A, Lamanna, N, Tam, CS, Jacobs, R, Lansigan, F, Barr, PM, Shadman, M, Skarbnik, AP, Pu, JJ, Sehgal, AR, Schuster, SJ, Shah, NN, Ujjani, CS, Roeker, L, Orlandi, EM, Billio, A, Trentin, L, Spacek, M, Marchetti, M, Tedeschi, A, Ilariucci, F, Gaidano, G, Doubek, M, Farina, L, Molica, S, Di Raimondo, F, Coscia, M, Mauro, FR, de la Serna, J, Medina Perez, A, Ferrarini, I, Cimino, G, Cavallari, M, Cucci, R, Vignetti, M, Foa, R, and Ghia, P

Abstract

Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real-world patients and performed a matched adjusted indirect comparison with a cohort of patients treated with ibrutinib. One hundred and fifty-seven patients with creatinine clearance (CrCl) <70 mL/min and/or CIRS score >6 were treated with BR. The median age was 72 years; 69% of patients had ≥2 comorbidities and the median CrCl was 59.8 mL/min. 17.6% of patients carried TP53 disruption. The median progression-free survival (PFS) was 45 months; TP53 disruption was associated with a shorter PFS (P = 0.05). The overall survival (OS) at 12, 24, and 36 months was 96.2%, 90.1%, and 79.5%, respectively. TP53 disruption was associated with an increased risk of death (P = 0.01). Data on 162 patients ≥65 years treated with ibrutinib were analyzed and compared with 165 patients ≥65 years treated with BR. Factors predicting for a longer PFS at multivariable analysis in the total patient population treated with BR and ibrutinib were age (HR 1.06, 95% CI 1.02-1.10, P < 0.01) and treatment with ibrutinib (HR 0.55, 95% CI 0.33-0.93, P = 0.03). In a post hoc analysis of patients in advanced stage, a significant PFS advantage was observed in patient who had received ibrutinib (P = 0.03), who showed a trend for OS advantage (P = 0.08). We arrived at the following conclusions: (a) BR is a relatively effective first-line regimen in a real-world population of unfit patients without TP53 disruption, (b) ibrutinib provided longer disease control than BR in patients with advanced disease stage.

Published
2020

4. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

Author

Cuneo, A., Mato, A. R., Rigolin, G. M., Piciocchi, A., Gentile, Marino, Laurenti, Luca, Allan, J. N., Pagel, J. M., Brander, D. M., Hill, B. T., Winter, A., Lamanna, N., Tam, C. S., Jacobs, R., Lansigan, F., Barr, P. M., Shadman, M., Skarbnik, A. P., Pu, J. J., Sehgal, A. R., Schuster, S. J., Shah, N. N., Ujjani, C. S., Roeker, L., Orlandi, E. M., Billio, Atto, Trentin, L., Spacek, M., Marchetti, M., Tedeschi, Alessandra, Ilariucci, F., Gaidano, G., Doubek, M., Farina, L., Molica, Serena, Di Raimondo, F., Coscia, M., Mauro, F. R., de la Serna, J., Medina Perez, A., Ferrarini, I., Cimino, Giovanni, Cavallari, M., Cucci, R., Vignetti, M., Foa, Robin, Ghia, P., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Billio A., Tedeschi A., Molica S., Cimino G., Foa R., Cuneo, A., Mato, A. R., Rigolin, G. M., Piciocchi, A., Gentile, Marino, Laurenti, Luca, Allan, J. N., Pagel, J. M., Brander, D. M., Hill, B. T., Winter, A., Lamanna, N., Tam, C. S., Jacobs, R., Lansigan, F., Barr, P. M., Shadman, M., Skarbnik, A. P., Pu, J. J., Sehgal, A. R., Schuster, S. J., Shah, N. N., Ujjani, C. S., Roeker, L., Orlandi, E. M., Billio, Atto, Trentin, L., Spacek, M., Marchetti, M., Tedeschi, Alessandra, Ilariucci, F., Gaidano, G., Doubek, M., Farina, L., Molica, Serena, Di Raimondo, F., Coscia, M., Mauro, F. R., de la Serna, J., Medina Perez, A., Ferrarini, I., Cimino, Giovanni, Cavallari, M., Cucci, R., Vignetti, M., Foa, Robin, Ghia, P., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Billio A., Tedeschi A., Molica S., Cimino G., and Foa R.

Abstract

Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real-world patients and performed a matched adjusted indirect comparison with a cohort of patients treated with ibrutinib. One hundred and fifty-seven patients with creatinine clearance (CrCl) <70 mL/min and/or CIRS score >6 were treated with BR. The median age was 72 years; 69% of patients had ≥2 comorbidities and the median CrCl was 59.8 mL/min. 17.6% of patients carried TP53 disruption. The median progression-free survival (PFS) was 45 months; TP53 disruption was associated with a shorter PFS (P = 0.05). The overall survival (OS) at 12, 24, and 36 months was 96.2%, 90.1%, and 79.5%, respectively. TP53 disruption was associated with an increased risk of death (P = 0.01). Data on 162 patients ≥65 years treated with ibrutinib were analyzed and compared with 165 patients ≥65 years treated with BR. Factors predicting for a longer PFS at multivariable analysis in the total patient population treated with BR and ibrutinib were age (HR 1.06, 95% CI 1.02-1.10, P < 0.01) and treatment with ibrutinib (HR 0.55, 95% CI 0.33-0.93, P = 0.03). In a post hoc analysis of patients in advanced stage, a significant PFS advantage was observed in patient who had received ibrutinib (P = 0.03), who showed a trend for OS advantage (P = 0.08). We arrived at the following conclusions: (a) BR is a relatively effective first-line regimen in a real-world population of unfit patients without TP53 disruption, (b) ibrutinib provided longer disease control than BR in patients with advanced disease stage.

Published
2020

5. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency

Author

Arcioni, F., Roncadori, A., Di Battista, V., Tura, S., Covezzoli, A., Cundari, S., Mecucci, C., Abbadessa, A., Alterini, R., Santini, V., Cantonetti, M., Buccisano, F., Bacigalupo, A., Sessarego, M., Tonso, A., Ferrero, D., D'Ardia, S., Tarella, C., Cascavilla, N., Bassan, R., Sancetta, R., Cortelezzi, A., Reda, G., Maria D'Arco, A., De Fabritiis, P., Di Renzo, N., Falini, B., Alimena, G., Avanzini, P., Ilariucci, F., Iuliano, F., La Nasa, G., Caocci, G., Defina, M., Latte, G., Palmas, A., Levis, A., Leone, G., Teresa Voso, M., Leoni, P., Poloni, A., Fozza, C., Crugnola, M., Montanaro, M., Spedini, P., Lanza, F., Pizzuti, M., Pane, F., Paolini, R., Borin, L., Rambaldi, A., Rossi, G., Maria Pelizzari, A., Russo, D., D'Emilio, A., Ruggeri, M., Semenzato, G., Specchia, G., Tagariello, G., Sartori, R., Testore, F., Ciravegna, G., Marasca, R., Cimarosto, L., Fontanive, O., Visani, G., Arcioni, F., Roncadori, A., Di Battista, V., Tura, S., Covezzoli, A., Cundari, S., Mecucci, C., Abbadessa, A., Alterini, R., Santini, V., Cantonetti, M., Buccisano, F., Bacigalupo, A., Sessarego, M., Tonso, A., Ferrero, D., D'Ardia, S., Tarella, C., Cascavilla, N., Bassan, R., Sancetta, R., Cortelezzi, A., Reda, G., Maria D'Arco, A., De Fabritiis, P., Di Renzo, N., Falini, B., Alimena, G., Avanzini, P., Ilariucci, F., Iuliano, F., La Nasa, G., Caocci, G., Defina, M., Latte, G., Palmas, A., Levis, A., Leone, G., Teresa Voso, M., Leoni, P., Poloni, A., Fozza, C., Crugnola, M., Montanaro, M., Spedini, P., Lanza, F., Pizzuti, M., Pane, F., Paolini, R., Borin, L., Rambaldi, A., Rossi, G., Maria Pelizzari, A., Russo, D., D'Emilio, A., Ruggeri, M., Semenzato, G., Specchia, G., Tagariello, G., Sartori, R., Testore, F., Ciravegna, G., Marasca, R., Cimarosto, L., Fontanive, O., and Visani, G.

Subjects
Oncology, Myeloid, Male, Group B, Immunologic Factor, 0302 clinical medicine, Retrospective Studie, hemic and lymphatic diseases, del(5q), Prospective Studies, Registries, Prospective cohort study, Hematology, Leukemia, registry study, Standard treatment, Remission Induction, General Medicine, Middle Aged, lenalidomide, myelodysplastic syndromes, Aged, Chromosomes, Human, Pair 5, Disease Progression, Female, Humans, Immunologic Factors, Italy, Karyotyping, Lenalidomide, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Retrospective Studies, Thalidomide, Chromosome Deletion, 030220 oncology & carcinogenesis, Pair 5, medicine.drug, Human, medicine.medical_specialty, Myelodysplastic Syndrome, Acute, Chromosomes, NO, 03 medical and health sciences, Internal medicine, medicine, business.industry, Myelodysplastic syndromes, Retrospective cohort study, medicine.disease, Settore MED/15, Prospective Studie, business, 030215 immunology
Abstract

Objective The most typical cytogenetic aberration in myelodysplastic syndromes is del(5q), which, when isolated, is associated with refractory anaemia and good prognosis. Based on high rates of erythroid response and transfusion independence, Lenalidomide (LEN) became the standard treatment. This multi-centre study was designed to supplement Italian Registry data on LEN by addressing prescription, administration appropriateness, haematological and cytogenetic responses and disease evolution. Methods MORE study was an observational, non-interventional, multi-centre, retrospective and prospective study. Cases were recruited from 45 Haematological Centres throughout Italy. Data were collected from the Italian National Registry for Lenalidomide administration and supplemented by a MORE data form. Results Data from 190/213 patients were analysed. In all, 149 had been diagnosed by conventional cytogenetics (GROUP A) and 41 only by FISH (GROUP B). Overall erythroid response was obtained in 92.8% of cases. Overall cytogenetic remission was achieved in 22.6% of cases. Disease progression occurred in 15.6% of cases. Clonal cytogenetic evolution characterised progression to AML but not to higher risk MDS. Conclusions Erythroid response to Lenalidomide was similar in MDS with isolated del(5q) and with del(5q) plus one anomaly. Progression to AML or higher risk MDS showed different cytogenetic features.

Published
2018

6. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma

Author

Ferreri, A.J.M., Campo, E., Ambrosetti, A., Ilariucci, F., Seymour, J.F., Willemze, R., Arrigoni, G., Rossi, G., López-Guillermo, A., Berti, E., Eriksson, M., Federico, M., Cortelazzo, S., Govi, S., Frungillo, N., Dell'Oro, S., Lestani, M., Asioli, S., Pedrinis, E., Ungari, M., Motta, T., Rossi, R., Artusi, T., Iuzzolino, P., Zucca, E., Cavalli, F., and Ponzoni, M.

Published
2004
Full Text
View/download PDF

8. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Author

Cuneo, A, Follows, G, Rigolin, GM, Piciocchi, A, Tedeschi, A, Trentin, L, Perez, AM, Coscia, M, Laurenti, L, Musuraca, G, Farina, L, Delgado, AR, Orlandi, EM, Galieni, P, Mauro, FR, Visco, C, Amendola, A, Billio, A, Marasca, R, Chiarenza, A, Meneghini, V, Ilariucci, F, Marchetti, M, Molica, S, Re, F, Gaidano, G, Gonzalez, M, Forconi, F, Ciolli, S, Cortelezzi, A, Montillo, M, Smolej, L, Schuh, A, Eyre, TA, Kennedy, B, Bowles, KM, Vignetti, M, de la Seam, J, Moreno, C, Foa, R, Ghia, P, GIMEMA, European Res Initiative CLL ERIC, and UK CLL Forum

Abstract

We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion. (Registered at clinicaltrials.gov identifier: 02491398)

Published
2018

9. PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Author

Mauro, F.R., primary, Molica, S., additional, Paoloni, F., additional, Reda, G., additional, Trentin, L., additional, Marchetti, M., additional, Pietrasanta, D., additional, Coscia, M., additional, Marasca, R., additional, Sportoletti, P., additional, Gaidano, G., additional, Orsucci, L., additional, Stelitano, C., additional, Di Renzo, N., additional, Liberati, A.M., additional, Gottardi, D., additional, Re, F., additional, Ilariucci, F., additional, Zinzani, P., additional, Mannina, D., additional, Gozzetti, A., additional, Molinari, A.L., additional, Gentile, M., additional, Consoli, U., additional, Laurenti, L., additional, Arcaini, L., additional, Ibatici, A., additional, Murru, R., additional, Tani, M., additional, De Propris, M.S., additional, Del Giudice, I., additional, Della Starza, I., additional, Raponi, S., additional, Nanni, M., additional, Fazi, P., additional, Crea, E., additional, Neri, A., additional, Specchia, G., additional, Guarini, A.R., additional, Cuneo, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

10. PHASE II FIL-PTCL13 STUDY OF ROMIDEPSIN-CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS

Author

Chiappella, A., primary, Carniti, C., additional, Evangelista, A., additional, Re, A., additional, Cabras, M.G., additional, Stefoni, V., additional, Castellino, C., additional, Congiu, A.G., additional, Pinto, A., additional, Zanni, M., additional, Rusconi, C., additional, Molinari, A.L., additional, Ciancia, R., additional, Baldini, L., additional, Nassi, L., additional, Re, F., additional, Tani, M., additional, Ilariucci, F., additional, Cavallo, F., additional, Santoro, A., additional, Volpetti, S., additional, Dodero, A., additional, Pileri, S.A., additional, Ciccone, G., additional, and Corradini, P., additional

Published
2019
Full Text
View/download PDF

11. FRONT-LINE THERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE, OFATUMUMAB (FC-O2) IN YOUNG (<= 65 YRS) AND FIT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. RESULTS OF THE PROSPECTIVE PHASE 2 GIMEMA STUDY LLC0911

Author

Mauro, Fr, Molica, S, Zaja, F, Piciocchi, A, Ilariucci, F, Coscia, M, Carella, Am, Re, F, Liberati, Am, Tedeschi, A, Gozzetti, A, Cuneo, A, Cortelezzi, A, Baraldi, A, Del Poeta, G, Musolino, C, Battistini, R, De Propris, Ms, Della Starza, I, Raponi, S, Ilari, C, Cafforio, L, Nanni, M, Fazi, P, Vignetti, M, Russo, F, Porrazzo, M, Riemma, C, Specchia, G, Neri, A, Guarini, A, and Foa, R

Published
2017

12. Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial

Author

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E., Illerhaus, G., Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E., and Illerhaus, G.

Published
2017

13. THE IELSG-32 TRIAL: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION VS HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA

Author

Ferreri, Ajm, Cwynarski, K, Pulczynski, E, Ponzoni, M, Politi, Ls, Ambrosetti, A, Vitolo, U, Ilariucci, F, Balzarotti, M, Fabbri, A, Tucci, A, Pisani, F, Levis, A, Cabras, Mg, D'Arco, M, Zaccaria, A, Angrilli, F, Guarini, Anna, Imola, M, Martelli, Maurizio, Cervetti, J, Zaja, F, Pinto, A, Liberati, M, Morra, E, Cortellazzo, Sf, Bassan, R, Foppoli, M, Citterio, G, Sassone, M, Scarfo, L, Cavalli, F, Finke, J, Reni, M, Zucca, E, and Illerhaus, G.

Published
2015

14. A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY

Author

Gentile, M., Shanafelt, T. D., Giovanna Cutrona, Molica, S., Tripepi, G., Ilariucci, F., Mauro, F. R., Di Renzo, N., Di Raimondo, F., Vincelli, I., Todoerti, K., Matis, S., Musolino, C., Maura, F., Fabris, S., Lionetti, M., Levato, L., Zupo, S., Angrilli, F., Consoli, U., Festini, G., Longo, G., Cortelezzi, A., Musto, P., Federico, M., Mannina, D., Neri, A., Kay, N. E., Ferrarini, M., and Morabito, F.

Published
2015

15. Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera

Author

Landolfi, R, Marchioli, R, Kutti, J, Gisslinger, H, Tognoni, G, Patrono, C, Barbui, T, Finazzi, G, Pusterla, S, Falanga, A, Galli, M, Wadenvik, H, Gastl, G, Ludescher, C, Lutz, D, Girschikofsky, M, Michlmayr, G, Rechberger, E, Niessner, H, Ivansich, E, Rain, Jd, Chommienne Thomas, C, Hehlmann, R, Engelich, G, Kohne, E, Kramer, A, Christakis, Ji, Papaioannou, M, Gerotziafas, G, O'Donnell, R, Bennett, M, Lugassy, G, Ellis, M, Eldor, A, Naparstek, E, Marilus, R, Leoni, P, Rupoli, S, Scortechini, Ar, Agostini, V, Volpe, E, Calmieri, F, Volpe, A, Storti, G, Ciampa, A, Dammacco, F, Lauta, Vm, Ranieri, G, Rizzi, R, Orsola, S, Tura, S, Finelli, C, Marino, G, Rossi, G, Almici, C, Capucci, A, Zanetti, F, Giustolisi, R, Cacciola, Rr, Cacciola, E, Peta, A, Magro, D, Frigerio, G, Alberio, F, Beretta, A, Bonferroni, M, Raviolo, A, Ferrini, Prl, Grossi, A, Fabbri, A, Nardelli, S, Centra, A, Musolino, C, Bellomo, G, Trincali, O, Spatari, Giovanna, Foa, P, Gerli, G, Carraro, Mc, Zanella, A, Lurlo, A, Barraco, F, Torelli, G, Marietta, M, Pogliani, E, Miccolis, Ir, La Rocca, A, Puglisi, A, Sardeo, G, Rotoli, B, Martinelli, V, Ciancia, R, Cardarelli, A, Cimino, R, Fasanaro, A, Randi, Ml, Rizzoli, V, Caramatti, C, Gaeta, L, Lazzarino, M, Passamonti, F, Lazzola, M, Malabarba, L, Natale, D, Pulini, S, Davi, G, Gugliotta, L, Ilariucci, F, De Candia, E, Eugenio, S, Amadori, S, Buccisano, F, Mandelli, F, Montefusco, E, Petti, Mc, Spadea, A, Carotenuto, M, Morelli, A, Nobile, M, Longinotti, M, Pardini, Sm, Lauria, F, Buccalossi, A, Gentili, S, Mazza, P, Cervellera, M, Maggi, A, Di Francesco, A, Pasqualoni, E, Chisesi, T, Polacco, A, Capnist, G, Rodeghiero, F, Ruggeri, M, Arrizabalaga, B, Remacha, A, De Mendiguren, Bp, Hernandez Nieto, L, Hernandez Garcia, Mt, Gonzalez Brito, G, Machado, P, Garcia, G, Villegas, A, Pena, A, Fernandez, Ag, Carbonell, F, Del Arco, A, Back, H, Stenke, L, Hansen, S, Larsson, G, Stromblad, G, Lauri, B, Ryden, Bo, Linder, O, Lundholm, Bg, Lannemyr, O, Strandberg, M, Andreasson, B, Stockelberg, D, Pasquariello, F, Tichelli, A, Otremba, B, Hinrichs, Hf, Weber Stadelmann, W, Bareford, D, Oscier, Dg, Bowey, N, Taylor, Pc, de Gaetano, G, Najean, Y, Pearson, Tc, Di Blasio, A, Atashkar, S, Mari, E, Tamayo, D, Borelli, G, Ferri, B, Marfisi, Rm, Olivieri, M, Polidoro, A, Spoltore, R, Levantesi, G, Di Mascio, R, Miceli, G, Sperti, G, Correale, E, Vermjlen, J, and Collins, R.

Subjects
Aspirin, medicine.medical_specialty, business.industry, food and beverages, General Medicine, medicine.disease, Thrombosis, Pulmonary embolism, Venous thrombosis, Polycythemia vera, Relative risk, Internal medicine, Anesthesia, Cardiology, Medicine, Myocardial infarction, business, Contraindication, medicine.drug
Abstract

background The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial. methods We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. results Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). conclusions Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment.

Published
2004

16. Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori-Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-III Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Author

Govi S, Patti C, Raderer M, Andriani A, Caraciolo D, Guidetti A, Ilariucci F, Luminari S, Mule A, Viale E, Arcidiacono PG, PONZONI , MAURILIO, Ferreri AJM, Govi, S, Patti, C, Raderer, M, Andriani, A, Caraciolo, D, Guidetti, A, Ilariucci, F, Luminari, S, Mule, A, Viale, E, Arcidiacono, Pg, Ponzoni, Maurilio, and Ferreri, Ajm

Published
2011

17. RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE (HD-MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (HD-ARAC) FOR PATIENTS WITH PRIMARY CNS LYMPHOMA (IELSG # 20 TRIAL): TOLERABILITY, ACTIVITY AND SURVIVAL ANALYSES

Author

Ferreri AJM, Reni M, Foppoli M, Martelli M, Siakantaris M, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Gelemur M, Aondio GM, Avvisati G, Balzarotti M, Brandes A, Costa MJ, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F, Ferreri, Ajm, Reni, M, Foppoli, M, Martelli, M, Siakantaris, M, Frezzato, M, Cabras, Mg, Fabbri, A, Corazzelli, G, Ilariucci, F, Rossi, G, Soffietti, R, Stelitano, C, Vallisa, D, Zaja, F, Gelemur, M, Aondio, Gm, Avvisati, G, Balzarotti, M, Brandes, A, Costa, Mj, Gomez, H, Guarini, A, Pinotti, G, Rigacci, L, Uhlmann, C, Ponzoni, M, Zucca, E, Caligaris-Cappio, F, and Cavalli, F

Published
2009

18. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study

Author

Gentile, M, Cutrona, G, Mosca, L, Matis, S, Fabris, S, Lionetti, M, Ilariucci, F, Zupo, S, Musolino, C, Levato, L, Molica, S, DI RAIMONDO, Francesco, Vincelli, I, Di Rienzo, N, Pesce, Ea, Angrilli, F, Federico, M, Neri, A, Ferrarini, M, and Morabito, F.

Subjects
Male, Gene Expression Profiling, Reproducibility of Results, Biological markers, chronic lymphocytic leukemia, early stage, gene expression profiles, prognosis, Middle Aged, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Risk Assessment, biological markers, Disease-Free Survival, Cohort Studies, Predictive Value of Tests, Biomarkers, Tumor, Disease Progression, Humans, Female, Prospective Studies
Abstract

A risk score based on three biological features (CD38, ZAP-70, and IGHV mutational status) was previously developed to predict progression-free survival (PFS) in untreated Binet A CLL patients. Here we perform a score validation analysis in a prospective and independent cohort of patients. Biological markers (CD38, ZAP-70, and IGHV mutational status) and gene expression profiles (GEP) of leukemic cells from CLL patients included in a prospective multicenter observational study (O-CLL1-GISL protocol, clinicaltrial.gov ID:NCT00917549) were used to assess the value and reproducibility of this score. To date, 468 Binet A patients were classified as low- (0 positive marker), intermediate- (1 positive marker), or high-risk (2 or 3 positive markers) using the progression risk score. The 3-year PFS probability was 91.7%, 82.9%, and 57.4% for low-, intermediate-, and high-risk (P 0.0001) cases, respectively. These values were similar to those found in the original cohort. At Cox multivariate analysis, Rai stage, absolute lymphocyte count, progression risk score, and β-2 microglobulin maintained an independent prognostic impact on PFS. This score remained a predictor of progression when analysis was limited to 371 Rai 0 cases (P 0.0001). Finally, the cells from the different CLL risk groups showed differences in their gene expression patterns. These results confirm the ability of this progression risk score to predict PFS among Binet A patients. The utility of the score was also extended by demonstrating that it retains prognostic value when applied exclusively to Rai 0 patients. Specific transcriptional patterns were significantly associated with risk groups.

Published
2014

19. ANTRACYCLINE BASED CHEMOTHERAPY AS PRIMARY TREATMENT FOR INTRAVASCULAR LYMPHOMA

Author

Ferreri, A, Campo, E, Ambrosetti, A, Ilariucci, F, Seymour, J, Willemze, R, Arrigoni, G, Rossi, G, LOPEZ GUILLERMO, A, Berti, E, Eriksson, M, Federico, M, Cortelazzo, S, Govi, S, Frungillo, N, Dell'Oro, S, Lestani, M, Asioli, S, Pedrinis, E, Ungari, M, Motta, T, Rossi, R, Artusi, T, Izzulino, P, Zucca, E, Cavalli, F, Ponzoni, M, FERRERI, A, CAMPO, E, AMBROSETTI, A, ILARIUCCI, F, SEYMOUR, J, WILLEMZE, R, ARRIGONI, G, ROSSI, G, ERIKSSON, M, FEDERICO, M, CORTELAZZO, S, GOVI, S, FRUNGILLO, N, DELL'ORO, S, LESTANI, M, ASIOLI, S, PEDRINIS, E, UNGARI, M, MOTTA, T, ROSSI, R, ARTUSI, T, IZZULINO, P, ZUCCA, E, CAVALLI, F, PONZONI, M., BERTI, EMILIO, Ferreri, A, Campo, E, Ambrosetti, A, Ilariucci, F, Seymour, J, Willemze, R, Arrigoni, G, Rossi, G, LOPEZ GUILLERMO, A, Berti, E, Eriksson, M, Federico, M, Cortelazzo, S, Govi, S, Frungillo, N, Dell'Oro, S, Lestani, M, Asioli, S, Pedrinis, E, Ungari, M, Motta, T, Rossi, R, Artusi, T, Izzulino, P, Zucca, E, Cavalli, F, Ponzoni, M, FERRERI, A, CAMPO, E, AMBROSETTI, A, ILARIUCCI, F, SEYMOUR, J, WILLEMZE, R, ARRIGONI, G, ROSSI, G, ERIKSSON, M, FEDERICO, M, CORTELAZZO, S, GOVI, S, FRUNGILLO, N, DELL'ORO, S, LESTANI, M, ASIOLI, S, PEDRINIS, E, UNGARI, M, MOTTA, T, ROSSI, R, ARTUSI, T, IZZULINO, P, ZUCCA, E, CAVALLI, F, PONZONI, M., and BERTI, EMILIO

Abstract

Background: Optimal therapeutic management of intravascular lymphoma (IVL) lacks precise guidelines. Patients and methods: The clinico-pathological features of 38 HIV-negative patients with IVL were reviewed to define efficacy of chemotherapy in these malignancies. Clinical characteristics of 22 patients treated with chemotherapy and of 16 untreated patients were compared in order to understand better the impact and causes of potential patient selection. Results: Median age was 70 years (range 34-90), with a male/female ratio of 0.9; 23 (61%) patients had Eastern Cooperative Oncology Group performance status (ECOG-PS) >1; 21 (55%) had systemic symptoms. Cutaneous lesions and anemia were significantly more common among patients treated with chemotherapy; central nervous system (CNS) and renal involvement were significantly more common among untreated patients. Chemotherapy was associated with a response rate of 59% and a 3-year overall survival of 33 ± 11%. Five of six patients with CNS involvement received chemotherapy: four of them died early; only one patient, treated with adriamycin, cyclophosphamide, vincristine, methotrexate, bleomycin and prednisolone (MACOP-B) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), was alive at 19 months. High-dose chemotherapy supported by ASCT was indicated at diagnosis in another patient (43 years of age, stage I), who was alive at 71 months, and at relapse after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in two patients who died early after transplantation. PS ≤1, disease limited to the skin, stage I, and use of chemotherapy were independently associated with better outcome. Conclusions: Anthracycline-based chemotherapy is the standard treatment for IVL. However, survival is disappointing, with a relevant impact of diagnostic delay and lethal complications. More intensive combinations, containing drugs with higher CNS bioavailability, are needed in cases with brain involve

Published
2004

20. RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY (CHT) WITH HIGH-DOSE METHOTREXATE (MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (ARAC) FOR PATIENTS (PTS) WITH PRIMARY CNS LYMPHOMA (PCNSL): THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) #20 TRIAL

Author

Ferreri JM, Foppoli M, Martelli M, Pangalis G, Frezzato M, Cabras G, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio G, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Reni M, Zucca E, Cavalli F., PONZONI , MAURILIO, Ferreri, Jm, Foppoli, M, Martelli, M, Pangalis, G, Frezzato, M, Cabras, G, Fabbri, A, Corazzelli, G, Ilariucci, F, Rossi, G, Soffietti, R, Stelitano, C, Vallisa, D, Zaja, F, Zoppegno, L, Aondio, G, Avvisati, G, Balzarotti, M, Brandes, Aa, Fajardo, J, Gomez, H, Guarini, A, Pinotti, G, Rigacci, L, Uhlmann, C, Ponzoni, Maurilio, Reni, M, Zucca, E, and Cavalli, F.

Published
2008

21. Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (PTS) with primary CNS lymphoma (PCNSL)

Author

Ferreri AJ, Foppoli M, Martelli M, Pangalis G, Frezzato M, Cabras G, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio G, Annibali O, Balzarotti M, Brandes A, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Reni M, Zucca E, Cavalli F., PONZONI , MAURILIO, Ferreri, Aj, Foppoli, M, Martelli, M, Pangalis, G, Frezzato, M, Cabras, G, Fabbri, A, Corazzelli, G, Ilariucci, F, Rossi, G, Soffietti, R, Stelitano, C, Vallisa, D, Zaja, F, Zoppegno, L, Aondio, G, Annibali, O, Balzarotti, M, Brandes, A, Fajardo, J, Gomez, H, Guarini, A, Pinotti, G, Rigacci, L, Uhlmann, C, Ponzoni, Maurilio, Reni, M, Zucca, E, and Cavalli, F.

Published
2008

24. Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial

Author

Illerhaus, G., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Fox, C. P., La Rose, P., Ambrosetti, A., Roeth, A., Hemmaway, A., Ilariucci, F., Linton, K. M., Soffietti, R., Pukrop, T., Binder, M., Balzarotti, M., Fabbri, A., Johnson, P., Gorlov, J. S., Cavalli, F., Finke, J., Schorb, E., Reni, M., Zucca, E., Ferrer, A. J. M., Illerhaus, G., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., Fox, C. P., La Rose, P., Ambrosetti, A., Roeth, A., Hemmaway, A., Ilariucci, F., Linton, K. M., Soffietti, R., Pukrop, T., Binder, M., Balzarotti, M., Fabbri, A., Johnson, P., Gorlov, J. S., Cavalli, F., Finke, J., Schorb, E., Reni, M., Zucca, E., and Ferrer, A. J. M.

Published
2015

25. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'

Author

Ferreri AJM, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, Lopez Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, PONZONI , MAURILIO, Ferreri A.J., Campo E., Seymour J.F., Willemze R, Illarucci F., Ambrosetti A., Zucca E., Rossi G., Lopez-Guillermo A., Pavlosky M.A., Geerts M.-L., Candoni A., Lestani M., Asioli S., Milani M., Piris M.A., Pileri S., Facchetti F., Cavalli F., Ponzoni M., Ferreri, Ajm, Campo, E, Seymour, Jf, Willemze, R, Ilariucci, F, Ambrosetti, A, Zucca, E, Rossi, G, Lopez Guillermo, A, Pavlovsky, Ma, Geerts, Ml, Candoni, A, Lestani, M, Asioli, S, Milani, M, Piris, Ma, Pileri, S, Facchetti, F, Cavalli, F, and Ponzoni, Maurilio

Subjects
Central nervous system lymphomas, Adult, Aged, 80 and over, Male, Intravascular lymphoma, prognosis, Skin Neoplasms, Lymphoma, Angiotropic lymphoma, Cutaneous lymphoma, Extranodal lymphoma, Middle Aged, Survival Analysis, Vascular Neoplasms, Neoplasms, Multiple Primary, HIV Seronegativity, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Aged, Neoplasm Staging
Abstract

Despite its recognition as a distinct, extremely rare entity, no large studies of intravascular lymphoma (IVL) have been reported. The clinico-pathological characteristics of 38 human immunodeficiency virus-negative patients with IVL diagnosed in Western countries were reviewed to better delineate clinical presentation, clinical variants, natural history and optimal therapy. The IVL is an aggressive and usually disseminated disease (Ann Arbor stage IV in 68% of cases) that predominantly affects elderly patients (median age 70 years, range: 34-90; male:female ratio 0.9), resulting in poor Eastern Cooperative Oncology Group Performance Status (ECOG-PS >1 in 61%), B symptoms (55%), anaemia (63%) and high serum lactate dehydrogenase level (86%). The brain and skin are the most common sites of disease. In contrast to previous reports, hepatosplenic involvement (26%) and bone marrow infiltration (32%) were found to be common features in IVL, while nodal disease was confirmed as rare (11% of cases). Patients with disease limited to the skin ('cutaneous variant'; 26% of cases) were invariably females with a normal platelet count, and exhibited a significantly better outcome than the remaining patients, which deserves further investigation. Overall survival was usually poor; however, the early use of intensive therapies could improve outcome in young patients with unfavourable features. ECOG-PS >1, 'cutaneous variant', stage I and chemotherapy use were independently associated with improved survival.

Published
2004

26. R-CHOP vs R-miniCEOP for the initial treatment of elderly 'fit' patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL)

Author

Merli, F, Luminari, S, Rossi, G., Mammi, C., Marcheselli, L., Tucci, A., Ilariucci, F., Chiappella, A., Musso, M., Di Rocco, A., Stelitano, C., Alvarez, I., Baldini, L., Mazza, P., Salvi, F., Arcari, A., Fragasso, A., Gobbi, P. G., Liberati, Anna Marina, and Federico, M.

Subjects
fit patients, R-CHOP, diffuse large B-cell lymphoma, R-miniCEOP, elderly
Published
2012

27. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

Author

Merli, Fabio, Luminari, S, Ilariucci, F, Petrini, Mario, Visco, C, Ambrosetti, A, Stelitano, C, Caracciolo, F, Di Renzo, N, Angrilli, F, Carella, Am, Capodanno, I, Barbolini, E, Galimberti, Sara, and Federico, M.

Subjects
Murine-Derived, Adult, Genetic Markers, Lymphoma, chemioterapia, mantle cell lymphoma, Kaplan-Meier Estimate, Lymphoma, Mantle-Cell, R-HCVAD, Infections, Antibodies, Dexamethasone, Disease-Free Survival, Drug Administration Schedule, Antibodies, Monoclonal, Murine-Derived, Young Adult, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Prospective Studies, Aged, Cyclophosphamide, Cytarabine, Doxorubicin, Follow-Up Studies, Hematologic Diseases, Infection, Methotrexate, Middle Aged, Rituximab, Treatment Outcome, Vincristine, treatment, Linfoma mantellare, Mantle-Cell
Abstract

This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P0·001). This multicentre study confirms that R-HCVAD-AM is an active regimen for the initial treatment of patients with MCL, but is associated with significant toxicity.

Published
2011

29. Dose-dense therapy with non-pegylated liposomal doxorubicin (R-comp 14 vs. 21) is feasible and effective for elderly patients with newly diagnosed aggresive B-cell non-Hodgkin lymphoma

Author

Visani, G., Merli, F., Angrilli, F., Ferrara, F., Ilariucci, F., Falorio, S., Fioritoni, G., Alesiani, F., Brunori, M., Pollio, F., Celentano, M., Cangini, D., Ronconi, S., Catarini, M., Giglio, G., Vallisa, D., Arcari, A., Bernardi, D., Paolini, R., Guiducci, B., Barulli, S., Lucesole, M., Rocchi, MARCO BRUNO LUIGI, Loscocco, F., D'Adamo, F., and Isidori, A.

Published
2010

30. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Author

Ferreri, A.J. Reni, M. Foppoli, M. Martelli, M. Pangalis, G.A. Frezzato, M. Cabras, M.G. Fabbri, A. Corazzelli, G. Ilariucci, F. Rossi, G. Soffietti, R. Stelitano, C. Vallisa, D. Zaja, F. Zoppegno, L. Aondio, G.M. Avvisati, G. Balzarotti, M. Brandes, A.A. Fajardo, J. Gomez, H. Guarini, A. Pinotti, G. Rigacci, L. Uhlmann, C. Picozzi, P. Vezzulli, P. Ponzoni, M. Zucca, E. Caligaris-Cappio, F. Cavalli, F.

Abstract

Background: Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy compared with high-dose methotrexate alone is unproven. We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma. Methods: This open, randomised, phase 2 trial was undertaken in 24 centres in six countries. 79 patients with non-Hodgkin lymphoma exclusively localised into the CNS, cranial nerves, or eyes, aged 18-75 years, and with Eastern Cooperative Oncology Group performance status of 3 or lower and measurable disease were centrally randomly assigned by computer to receive four courses of either methotrexate 3·5 g/m2 on day 1 (n=40) or methotrexate 3·5 g/m2 on day 1 plus cytarabine 2 g/m2 twice a day on days 2-3 (n=39). Both regimens were administered every 3 weeks and were followed by whole-brain irradiation. The primary endpoint was complete remission rate after chemotherapy. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00210314. Findings: All randomly assigned participants were analysed. After chemotherapy, seven patients given methotrexate and 18 given methotrexate plus cytarabine achieved a complete remission, with a complete remission rate of 18% (95% CI 6-30) and 46% (31-61), respectively, (p=0·006). Nine patients receiving methotrexate and nine receiving methotrexate plus cytarabine achieved a partial response, with an overall response rate of 40% (25-55) and 69% (55-83), respectively, (p=0·009). Grade 3-4 haematological toxicity was more common in the methotrexate plus cytarabine group than in the methotrexate group (36 [92%] vs six [15%]). Four patients died of toxic effects (three vs one). Interpretation: In patients aged 75 years and younger with primary CNS lymphoma, the addition of high-dose cytarabine to high-dose methotrexate provides improved outcome with acceptable toxicity compared with high-dose methotrexate alone. Funding: Swiss Cancer League. © 2009 Elsevier Ltd. All rights reserved.

Published
2009

33. the International Extranodal Lymphoma Study group (IELSG). Intravascular lymphoma: clinical presentation, natural history, management, and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'

Author

Ferreri, A. J., Campo, E, Seymour, Jf, Willemze, R, Ilariucci, F, Ambrosetti, Achille, Zucca, E, Rossi, G, LOPEZ GUILLERMO, A, Pavlovsky, Ma, Geerts, Ml, Candoni, A, Lestani, M, Asioli, S, Milani, M, Piris, Ma, Pileri, S, Facchetti, F, Cavalli, F, and Ponzoni, M.

Subjects
intravascular lymphoma, central nervous system lymphomas, cutaneous lymphoma, angiotropic lymphoma, extranodal lymphoma
Published
2004

34. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas

Author

Morabito, F., Gallamini, A., Stelitano, C., Callea, V., Guglielmi, C., Neri, S., Lazzaro, A., Orsucci, L., Ilariucci, F., Sacchi, S., Vitolo, U., Federico, M., Intergruppo Italiano Linfomi, and Liberati, Anna Marina

Subjects
Clinical outcome, unspecified, Peripheral T-cell lymphoma, Diffuse large B-cell lymphoma, Prognosis, Immunophenotype, Peripheral T-cell lymphoma, unspecified
Published
2004

36. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL)

Author

Longo, G, Fiorani, C, Sacchi, S, Callea, V, Lombardo, M, Federico, M, Stelitano, C, Angrilli, F, Vallisa, D, Gobbi, Pg, Ilariucci, F, Frassoldati, A, Petrini, Mario, and Silingardi, V.

Subjects
Adult, Male, Adolescent, ALCL, CD30, chemotherapy, radiotherapy, survival, Middle Aged, Combined Modality Therapy, Survival Rate, Treatment Outcome, Humans, Female, Lymphoma, Large B-Cell, Diffuse, Aged
Abstract

Although in recent years anaplastic large-cell lymphoma (ALCL) has emerged as a distinct clinico-pathological entity, a gold standard for treatment has still not been defined. Goals of our histologic, phenotypic and clinical study were to present clinical findings, treatment outcome and survival rates of a small, but highly homogeneously treated, series of patients.From April 1991, 36 newly diagnosed adult patients with systemic ALCL CD30+, entered a prospective non-randomized trial in one of the institutions participating in a GISL (Gruppo Italiano per lo studio dei Linfomi) study and were treated with a MOPP/EBV/CAD hybrid scheme. Chemotherapy (CHT) was administered every 28 days, for a total of 6 cycles. After CHT, 19 patients received radiation therapy (RT) to the site of previously involved fields. Kaplan and Meier and log-rank tests were used for statistical analysis.The overall complete remission rate was 78%, the partial remission rate was 6%. The overall survival rate at 74 months was 69%. No statistically significant differences in response or survival rates were noted comparing ALCL-HL and -CT subgroups, T+ Null- and B- subtypes, or ALCL-HL and -CT, with different phenotypes. In the analysis of patients with T+ Null phenotype treated with CHT+RT in comparison with B-ALCL patients who had the same treatment, we observed statistically significant differences in the survival rate (p=0.048). No prognostic factors predictive of response or survival were identified.Our results show that using MOPP/ABV/CAD the results, in terms of remission rate and survival, are similar to those obtained with 3rd generation CHT regimens. The diagnosis of T and Null ALCL is the most important prognostic factor, because it is associated with a very good survival, even in patients with a high prognostic index. Finally, we believe that longer follow-ups are needed to evaluate long-term survival and toxicity with different treatments.

Published
1999

38. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system

Author

Baldini, L, Goldaniga, M, Guffanti, A, Broglia, C, Cortelazzo, S, Rossi, A, Morra, E, Colombi, M, Callea, V, Pogliani, E, Ilariucci, F, Luminari, S, Morel, P, Merlini, G, Gobbi, P, Gobbi, P., POGLIANI, ENRICO MARIA, Baldini, L, Goldaniga, M, Guffanti, A, Broglia, C, Cortelazzo, S, Rossi, A, Morra, E, Colombi, M, Callea, V, Pogliani, E, Ilariucci, F, Luminari, S, Morel, P, Merlini, G, Gobbi, P, Gobbi, P., and POGLIANI, ENRICO MARIA

Abstract

To evaluate the clinicohematologic variables at diagnosis that are prognostically related to neoplastic progression in patients with immunoglobulin M (IgM) monoclonal gammopathies of undetermined significance (MGUS), and indolent Waldenström's macroglobulinemia (IWM), and propose a scoring system to identify subsets of patients at different risk.

Published
2005

42. Temozolomide as salvage treatment in primary brain lymphomas

Author

Reni, M, primary, Zaja, F, additional, Mason, W, additional, Perry, J, additional, Mazza, E, additional, Spina, M, additional, Bordonaro, R, additional, Ilariucci, F, additional, Faedi, M, additional, Corazzelli, G, additional, Manno, P, additional, Franceschi, E, additional, Pace, A, additional, Candela, M, additional, Abbadessa, A, additional, Stelitano, C, additional, Latte, G, additional, and Ferreri, A J M, additional

Published
2007
Full Text
View/download PDF

44. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

Author

Ferreri, A.J.M., primary, Dell'Oro, S., additional, Foppoli, M., additional, Bernardi, M., additional, Brandes, A. A., additional, Tosoni, A., additional, Montanari, M., additional, Balzarotti, M., additional, Spina, M., additional, Ilariucci, F., additional, Zaja, F., additional, Stelitano, C., additional, Bobbio, F., additional, Corazzelli, G., additional, Baldini, L., additional, Ponzoni, M., additional, Picozzi, P., additional, Cappio, F. C., additional, and Reni, M., additional

Published
2006
Full Text
View/download PDF

46. Final results of a multicentre phase II trial of high-dose methotrexate (HD-MTX), cytarabine, thiotepa, and idarubicin (MATILDE regimen) followed by whole-brain irradiation (WBRT) for primary CNS lymphomas (PCNSL)

Author

Ferreri, A. J., primary, Dell’oro, S., additional, Foppoli, M., additional, Brandes, A. A., additional, Montanari, M., additional, Balzarotti, M., additional, Spina, M., additional, Ilariucci, F., additional, Zaja, F., additional, and Reni, M., additional

Published
2005
Full Text
View/download PDF

48. Clinical presentation, management and prognosis of angiotropic lymphoma in western countries: The IELSG experience on 37 HIV-negative cases

Author

Ferreri, Ajm, Campo, E., Seymour, Jf, Ambrosetti, A., Willemze, R., Ilariucci, F., Rossi, G., Armando, Lg, Emilio, B., Stefania, Do, Alessandro Stefano, Massimo, L., Facchetti, F., Cavalli, F., Ponzoni, M., Ferreri, Ajm, Campo, E, Seymour, Jf, Ambrosetti, A, Willemze, R, Ilariucci, F, Rossi, G, Armando, Lg, Emilio, B, Stefania, Do, Stefano, A, Massimo, L, Facchetti, F, Cavalli, F, and Ponzoni, Maurilio

50. VENETOCLAX AND RITUXIMAB (VENR) FOR THE FRONT-LINE TREATMENT OF YOUNG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND AN UNFAVORABLE BIOLOGIC PROFILE. PRELIMINARY RESULTS OF THE GIMEMA VERITAS STUDY

Author

Mauro, F. R., Reda, G., Arena, V., Visentin, A., Coscia, M., Sportoletti, P., Laurenti, L., Gaidano, G., Marasca, R., Orsucci, L., Murru, R., Stelitano, C., Ilariucci, F., Mannina, D., Massaia, M., Gian Matteo Rigolin, Scarfo, L., Marchetti, M., Levato, L., Tani, M., Arcari, A., Musuraca, G., Deodato, M., Galieni, P., Patrizi, V. Belsito, Gottardi, D., Liberati, A. M., Pietrasanta, D., Molica, S., Cassin, R., Vitale, C., Ielo, C., Propris, M. S., Della Starza, I., Raponi, S., Nanni, M., Del Giudice, I., Paoloni, F., Fazi, P., Albano, F., Neri, A., Piciocchi, A., Trentin, L., Cuneo, A., Guarini, A., and Foa, R.

Catalog

Books, media, physical & digital resources
See catalog results